HAE
HAEMONETICS CORP
$74.88
+5.05%
$3.4B
No data for this timeframe.
Vol
Market Cap$3.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders7 funds
Inst. Value$633.1M
Inst. Activity3 buys / 0 sells
SEC Reports4
Exchange NYSE·Sector Surgical & Medical Instruments & Apparatus·Inc. MA·CIK 0000313143·Prev Close $71.28
Recent Activity
Jun 9, 2026
SEC
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, filed by management.
DEFA14A — Impact 5/10
Jun 9, 2026
short_volume
Short Volume: HAE — 59.1% short (0.6M / 1.1M)
Short: 625,874 | Exempt: 33,791 | TRF Vol: 1,059,374 | Short Ratio: 59.1% | Off-exchange volume (dar
Jun 5, 2026
SEC
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood Center segments into
8-K — Impact 2/10
Jun 5, 2026
Insider
Miller Laurie A. sold 313 shares
SVP, Human Resources @ $71.28 ($22.3K)
Jun 5, 2026
Insider
Maunsell Farris Maryanne sold 259 shares
VP, Chief Accounting Officer @ $71.28 ($18.5K)
May 15, 2026
Insider
Simon, Christopher sold 9,681 shares
President & CEO @ $56.29 ($544.9K)
May 7, 2026
SEC
Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.29 edged past consen
8-K — Impact 4/10
Inst.
BANK OF AMERICA CORP — ADD
482,165 shares ($38.6M)
Price Targets
$81.60
+3.7% upside
Hold
Current $78.71
Low $62.00
Median $82.00
High $104.00
10 analysts
$62.00
$104.00
Analyst Ratings
5Strong Buy
6Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| May 22, 2026 | B of A Securities | UPGRADE | Neutral → Buy |
| May 12, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| May 8, 2026 | JP Morgan | MAINTAIN | Neutral → Neutral |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.10 ▼ -5.4% | $1.03 — $1.22 | 0% YoY | 11 |
| Next Q | $1.27 ▼ -3.8% | $1.19 — $1.34 | 0% YoY | 11 |
| Current FY | $5.22 ▼ -1.3% | $5.17 — $5.26 | 5% YoY | 11 |
| Next FY | $5.77 ▼ -2.4% | $5.51 — $6.11 | 10% YoY | 11 |
Latest Reports
NEUTRAL
DEFA14A
5/10
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, filed by management.
Jun 9, 2026
NEUTRAL
8-K
2/10
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood Center segments into
Jun 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $381.6M | — |
| FMR LLC | $106.4M | ADD |
| MORGAN STANLEY | $45.1M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $44.0M | NEW |
| BANK OF AMERICA CORP | $38.6M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Miller Laurie | F | $22.3K |
| Jun 5, 2026 | Maunsell Farris | F | $18.5K |
| May 15, 2026 | Simon, Christopher | F | $544.9K |
| May 15, 2026 | Simon, Christopher | A | $0.00 |
| May 15, 2026 | Miller Laurie | F | $53.4K |
7 institutional holders with $633.1M total value (7,899,117 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,761,135 | $381.6M | 60.3% | — |
| 2 | FMR LLC | 1,326,902 | $106.4M | 16.8% | ADD +45.5% |
| 3 | MORGAN STANLEY | 562,949 | $45.1M | 7.1% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 548,921 | $44.0M | 6.9% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 482,165 | $38.6M | 6.1% | ADD +44.2% |
| 6 | NORGES BANK | 125,927 | $10.1M | 1.6% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 91,118 | $7.3M | 1.2% | ADD +75.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 334,301 | 482,165 | +44.2% | $38.6M | 2025-Q4 |
| NORGES BANK | NEW | — | 125,927 | — | $10.1M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 51,848 | 91,118 | +75.7% | $7.3M | 2025-Q4 |
| UBS Group AG | ADD | 869,789 | 1,530,071 | +75.9% | $74.6M | 2025-Q3 |
| FMR LLC | ADD | 835,847 | 1,215,829 | +45.5% | $59.3M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 679,491 | 334,301 | -50.8% | $16.3M | 2025-Q3 |
| NORGES BANK | EXIT | 493,520 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 7,122 | 0 | -100.0% | $0.00 | 2025-Q3 |
| UBS Group AG | DOUBLED | 416,097 | 869,789 | +109.0% | $64.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 493,520 | — | $36.8M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 28,205 | 47,073 | +66.9% | $3.5M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 7,122 | — | $531.4K | 2025-Q2 |
| UBS Group AG | DOUBLED | 192,512 | 416,097 | +116.1% | $26.4M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 281,944 | 416,080 | +47.6% | $26.4M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | TRIM | 37,883 | 28,205 | -25.5% | $1.8M | 2025-Q1 |
| NORGES BANK | EXIT | 420,116 | 0 | -100.0% | $0.00 | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 58,799 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 392,717 | 281,944 | -28.2% | $22.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 24,046 | 192,512 | +700.6% | $15.0M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 55,044 | 37,883 | -31.2% | $3.0M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 42,000 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 542,716 | — | $43.6M | 2024-Q3 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Miller Laurie A. | SVP, Human Resources | F | 313 | $71.28 | $22.3K |
| Jun 5, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | F | 259 | $71.28 | $18.5K |
| May 15, 2026 | Simon, Christopher | President & CEO | F | 9,681 | $56.29 | $544.9K |
| May 15, 2026 | Simon, Christopher | President & CEO | A | 78,344 | $0.00 | $0.00 |
| May 15, 2026 | Miller Laurie A. | SVP, Human Resources | F | 948 | $56.29 | $53.4K |
| May 15, 2026 | Miller Laurie A. | SVP, Human Resources | A | 13,323 | $0.00 | $0.00 |
| May 15, 2026 | Galvin Roy | EVP, Chief Commercial Officer | A | 27,535 | $0.00 | $0.00 |
| May 15, 2026 | Galvin Roy | EVP, Chief Commercial Officer | F | 879 | $56.29 | $49.5K |
| May 15, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | F | 197 | $56.29 | $11.1K |
| May 15, 2026 | Maunsell Farris Maryanne | VP, Chief Accounting Officer | A | 2,220 | $0.00 | $0.00 |
| May 15, 2026 | DArecca James | EVP, Chief Financial Officer | F | 2,505 | $56.29 | $141.0K |
| May 15, 2026 | DArecca James | EVP, Chief Financial Officer | A | 29,312 | $0.00 | $0.00 |
| May 15, 2026 | Chan Frank | EVP, Chief Operating Officer | F | 546 | $56.29 | $30.7K |
| May 15, 2026 | Chan Frank | EVP, Chief Operating Officer | A | 27,535 | $0.00 | $0.00 |
| May 15, 2026 | Basil Michelle L | EVP and General Counsel | F | 2,913 | $56.29 | $164.0K |
| May 15, 2026 | Basil Michelle L | EVP and General Counsel | A | 28,424 | $0.00 | $0.00 |
| May 1, 2026 | DArecca James | EVP, Chief Financial Officer | F | 655 | $59.26 | $38.8K |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.3/10.
NEUTRAL
DEFA14A
5/10
Haemonetics Corp filed definitive additional proxy soliciting materials (DEFA14A) on June 9, 2026, f
Jun 9, 2026
NEUTRAL
8-K
2/10
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood C
Jun 5, 2026
NEUTRAL
8-K
4/10
Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.
May 7, 2026
NEUTRAL
8-K
2/10
Director Charles J. Dockendorff will not stand for re-election at Haemonetics' 2026 annual meeting,
May 1, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (73% buy). Based on 15 analysts: 5 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$81.60 mean target
+3.7% upside
Hold (1.91)
$62.00 Low
$104.00 High
| Metric | Value |
|---|---|
| Current Price | $78.71 |
| Target Low | $62.00 |
| Target Mean | $81.60 |
| Target Median | $82.00 |
| Target High | $104.00 |
| # Analysts | 10 |
| Recommendation | Hold (1.91) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.10 | $1.03 | $1.22 | 0.2% | -5.4% | 2↑ 7↓ | $0.3B | 2.6% | 11 |
| Next Q 2026-09-30 |
$1.27 | $1.19 | $1.34 | 0.3% | -3.8% | 1↑ 7↓ | $0.3B | 4.8% | 11 |
| Current FY 2027-03-31 |
$5.22 | $5.17 | $5.26 | 5.3% | -1.3% | 2↑ 8↓ | $1.4B | 5.0% | 11 |
| Next FY 2028-03-31 |
$5.77 | $5.51 | $6.11 | 10.4% | -2.4% | 2↑ 5↓ | $1.5B | 5.3% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.102 | |
| 7d ago | $1.102 | |
| 30d ago | $1.164 | -0.062 |
| 60d ago | $1.167 | -0.065 |
| 90d ago | $1.167 | -0.065 |
8 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| May 22, 2026 | B of A Securities | UPGRADE | Neutral | Buy |
| May 12, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| May 8, 2026 | JP Morgan | MAINTAIN | Neutral | Neutral |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Apr 7, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Mar 11, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 6, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 6, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 6, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Feb 6, 2026 | BTIG | REITERATE | Buy | Buy |
| Feb 2, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Jan 12, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Jan 9, 2026 | BTIG | REITERATE | Buy | Buy |
| Dec 17, 2025 | Mizuho | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Baird | MAINTAIN | Outperform | Outperform |
| Dec 15, 2025 | Needham | DOWNGRADE | Buy | Hold |
| Dec 12, 2025 | JP Morgan | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 4 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Feb 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% | |
| Jan 1, 2026 | 4 | 6 | 5 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: HAE — 59.1% short (0.6M / 1.1M)
Short: 625,874 | Exempt: 33,791 | TRF Vol: 1,059,374 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: HAE — 81.5% short (0.5M / 0.6M)
Short: 478,124 | Exempt: 1,697 | TRF Vol: 586,813 | Short Ratio: 81.5% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
short_volume
Short Volume: HAE — 71.6% short (0.4M / 0.5M)
Short: 362,652 | Exempt: 0 | TRF Vol: 506,723 | Short Ratio: 71.6% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: HAE — 69.4% short (0.4M / 0.5M)
Short: 367,297 | Exempt: 4,400 | TRF Vol: 529,515 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: HAE — 57.6% short (0.3M / 0.6M)
Short: 345,121 | Exempt: 0 | TRF Vol: 599,684 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: HAE — 73,355 shares ($4.0M) failed to deliver
Settlement: 20260513, Price: $54.01, FTD Value: $3,961,903.55, HAEMONETICS CORP
May 7, 2026
earnings_calendar
HAE Q4 2026 Earnings After Market Close — 2026-05-07
May 6, 2026
short_volume
Short Volume: HAE — 61.6% short (0.3M / 0.5M)
Short: 320,331 | Exempt: 0 | TRF Vol: 519,741 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)